Ottawa Heart Institute Research Corporation

Open enrollment with a later-stage pipeline tilt

According to ClinicalTrials.gov-derived indexes, Ottawa Heart Institute Research Corporation sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 9 currently recruiting 1 completed later-stage tilt top decile by trial count

Ottawa Heart Institute Research Corporation: 10 sponsored US clinical trials, 9 recruiting.

Ottawa Heart Institute Research Corporation sponsors 10 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting, and 1 completed. 4 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Shock, Cardiogenic, with 1 trials.

Top-decile sponsor footprint

Ottawa Heart Institute Research Corporation ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING NA

Left Atrial Imaging Prior to Cardioversion: Leveraging Computed Tomography to Rule Out Thrombus in The Emergency Department (LA CLOTTED)

NCT07002450
RECRUITING Phase 3

Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm

NCT06281977
RECRUITING NA

Transcatheter Mitral Valve Repair for Inotrope Dependent Cardiogenic Shock

NCT05298124
RECRUITING Phase 4

CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

NCT05267886
RECRUITING Phase 3

Cardiac Sarcoidosis Randomized Trial

NCT03593759
RECRUITING Phase 3

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

NCT03630055
RECRUITING NA

Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

NCT03536312
RECRUITING NA

The Minimally Invasive Coronary Surgery Compared to STernotomy Coronary Artery Bypass Grafting Trial

NCT03447938
RECRUITING NA

Comparing Hypothermic Temperatures During Hemiarch Surgery

NCT02860364
COMPLETED NA

IMAGE-HF Project I-A: Cardiac Imaging in Ischemic Heart Failure (AIMI-HF)

NCT01288560

Phase Distribution

PhaseTrial count
Phase 3 3
Phase 4 1

Therapeutic Areas

Shock, Cardiogenic 1
Radial Artery Occlusion 1
Ascending Aorta Aneurysm 1
Ascending Aortic Aneurysm Enlargement 1
Cardiac Sarcoidosis 1
Thoracic Aortic Disease 1
Mitral Regurgitation 1
Coronary Artery Disease 1
Cardiogenic Shock 1
Sarcoidosis 1

Where Ottawa Heart Institute Research Corporation enrollment is open (later-stage tilt)

9 recruiting of 10 indexed (90% open); 1 completed (10%).

Phase mix: 4 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Shock, Cardiogenic (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Ottawa Heart Institute Research Corporation: open-pipeline peers nationwide

Peers matched on 10 registered trials and 90% open enrollment, not the therapeutic-area sidebar.

Ottawa Heart Institute Research Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 5101520 0%20%40%60%80%100% Total trials Recruiting share Ottawa Heart Institute Research CorporationAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsDualityBioEfforiaJuno Therapeutics, Inc., a Bristol-Myers Squibb CompanyJohnson & Johnson Enterprise Innovation
Ottawa Heart Institute Research Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Ottawa Heart Institute Research Corporation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 90% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Ottawa Heart Institute Research Corporation page

10 registered trials is a research-attention snapshot, not an endorsement of Ottawa Heart Institute Research Corporation or any single study.

  • 9 of Ottawa Heart Institute Research Corporation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Shock, Cardiogenic is the condition Ottawa Heart Institute Research Corporation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Shock, Cardiogenic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Ottawa Heart Institute Research Corporation pipeline card: 10 registered trials from official public datasets.Report a data error.